Brad D Maxwell

List of Publications by Year
in descending order

20 papers	865 citations	1307594 7 h-index	888059 17 g-index
21 all docs	21 docs citations	21 times ranked	1209 citing authors

#	Article	IF	Citations
1	Deuterated active pharmaceutical ingredients: A scienceâ€based proposal for synthesis, analysis, and control. Part 1: Framing the problem. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 690-694.	1.0	16
2	Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11Î²-Hydroxysteroid Dehydrogenase Type 1 (11Î²-HSD-1). ACS Medicinal Chemistry Letters, 2018, 9, 1170-1174.	2.8	2
3	New radical methods for the potential synthesis of carbonâ€13 and carbonâ€14 labeled complex products. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 1024-1035.	1.0	4
4	Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode. Journal of Medicinal Chemistry, 2017, 60, 1417-1431.	6.4	25
5	Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3â€²-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11Î²-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. Journal of Medicinal Chemistry, 2017, 60, 4932-4948.	6.4	10
6	The syntheses of [¹³C₆] and [phenylâ€¹⁴C(U)]BMSâ€816336, an inhibitor of 11Î²â€hydroxysteroid dehydrogenase type 1, for type 2 diabetes. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 357-365.	1.0	0
7	The synthesis of [1â€¹⁴C]2â€(1Hâ€tetrazolâ€5â€yl)acetic acid. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 49-54.	1.0	0
8	Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212). Journal of Medicinal Chemistry, 2017, 60, 9703-9723.	6.4	45
9	The synthesis of [¹⁴C]4â€acetylphenylalanine, effect on cell viability, and assessment of protein incorporation in male rat hepatocytes. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 352-356.	1.0	2
10	A general alkyl-alkyl cross-coupling enabled by redox-active esters and alkylzinc reagents. Science, 2016, 352, 801-805.	12.6	579
11	The synthesis and analysis of [phenyl-14C(U)]BMS-770767 and [13C6]BMS-770767 for use in discovery biotransformation, human ADME and bioanalytical studies. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 657-664.	1.0	1
12	The syntheses of isotopically labelled CBâ€1 antagonists for the treatment of obesity. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 665-672.	1.0	5
13	The syntheses of [14C]BMS-823778 for use in a human ADME clinical study and of [13CD313CD2]BMT-094817, a stable-isotope labeled standard of a newly detected human metabolite. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 255-259.	1.0	4
14	Editorial. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 232-232.	1.0	0
15	Hydromethylation of Unactivated Olefins. Journal of the American Chemical Society, 2015, 137, 8046-8049.	13.7	137
16	The synthesis of ¹⁴Câ€labeled Nâ€succinimidylâ€3â€maleimidopropionate, a linker molecule for PEGylated biologics. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 667-669.	1.0	1
17	The synthesis of a carbonâ€14 labeled pegylated Adnectinâ„¢ for placental transfer studies in guinea pigs. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 492-494.	1.0	5
18	An improved synthesis of [2-14C]2, 5-dichloropyrimidine. Journal of Labelled Compounds and Radiopharmaceuticals, 2012, 55, 300-302.	1.0	1

#	Article	IF	Citations
19	The syntheses and in vitro biotransformation studies of [¹⁴C]apixaban, a highly potent, selective, efficacious and orally bioavailable inhibitor of blood coagulation Factor Xa. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 418-425.	1.0	9
20	A novel synthesis of [2-14C]2,5-dichloropyrimidine. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 813-815.	1.0	3